Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043

Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 After a Single Ascending Bolus Dose, and a Single Ascending Bolus Dose Followed by a Single Infusion Dose in Healthy Volunteers

The primary purpose of this study is to assess the safety and tolerability of AZD3043 following administration of single ascending bolus doses (Part A) and single ascending bolus doses followed by infusion (Part B).

Inclusion Criteria:

• Subjects with suitable veins for cannulation or repeated venepuncture
• Pre-dose assessment judged without remarks by the investigator
• Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg

Exclusion Criteria:

• Abnormal vital signs, after 15 minutes supine rest, defined as any of the following:
• Systolic blood pressure >140 mm Hg
• Diastolic blood pressure >90 mm Hg
• Heart rate ≤45 or >85 beats per minute
• Lack of normal phenotype for BuChE (Butyrylcholinesterase)